Evolving role of 225Ac-PSMA radioligand therapy in metastatic castration-resistant prostate cancer-a systematic review and meta-analysis.

Swayamjeet SatapathyAshwani Sood Chandan Krushna DasBhagwant Rai Mittal

Published in: Prostate cancer and prostatic diseases (2021)

225Ac-PSMA RLT is an efficacious and safe treatment option for patients with mCRPC. Future randomized controlled trials are required to establish its therapeutic efficacy and survival benefit vis-à-vis other approved treatment modalities.

Keyphrases

pet ct
randomized controlled trial
squamous cell carcinoma
systematic review
stem cells
computed tomography
bone marrow
replacement therapy
free survival
double blind